CRA’s Andrew Tepperman provided expert testimony in multiple proceedings before the Patented Medicine Prices Review Board (PMPRB) in relation to alleged excessive pricing by pharmaceutical companies in Canada. CRA’s team addressed the application of published guidelines by the PMPRB, and the relationship between certain tests described in those guidelines and other means of evaluation whether drug prices are excessive.
CRA's RADAR Insights: Evolution of manufacturer-set list prices and GKV rebates for orphan drugs - Part 2
RADAR contains all orphan drugs (ODs) that received European Medicines Agency (EMA) marketing authorisation between July 1, 2013, and September 30, 2024. For...